$AXSM

Axsome Therapeutics' executives and board members were cleared of shareholder accusations regarding the company's communication about its migraine drug's regulatory approval. The derivative complaint lacked sufficient evidence of securities law violations, according to Judge Lorna G. Schofield's ruling. The case is related to a prior class action settlement.

RBC Capital reiterated an Outperform rating on Axsome Therapeutics (AXSM) with a $295 price target, noting a 28% stock decline in the past month. The firm attributes this to seasonal effects and sampling dynamics, not launch weakness. AXSM reported Q2 2026 revenue of $218.4M, beating H.C. Wainwright's forecast. Multiple firms raised price targets, citing growth potential in Alzheimer’s disease agitation treatment.

Axsome Therapeutics (AXSM) reports Auvelity's Q2 sales at $180.3M, up 51% YoY, with expansion into Alzheimer's agitation treatment. The company projects peak sales of $8B, split between depression and Alzheimer's. Axsome also has Sunosi and Symbravo in its portfolio, with a pipeline including AXS-12 and AXS-14. Q2 revenue was $218.4M, with a net loss of $51.3M due to high commercialization spending.

Axsome Therapeutics (AXSM) will report Q3 2026 financial results on November 2, 2026, before market open, followed by a conference call at 8:00 a.m. ET. The company develops treatments for central nervous system disorders and has FDA-approved products for conditions like major depressive disorder and migraine.

Wells Fargo named 13 stocks across seven sectors for its 4Q 2026 long ideas, all rated 'overweight' with expected 10%+ returns. Key picks include Roblox (bookings guidance $2.01B-$2.07B), Occidental Petroleum, and Microsoft. Price targets and catalysts are provided for each.

B. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.

Axsome Therapeutics (NASDAQ:AXSM) presented at the H.C. Wainwright Conference, highlighting growth for Auvelity, with estimated peak sales of over $8 billion. Sunosi and SYMBRAVO also showed potential, with peak sales estimates of $300M-$500M and $500M-$1B, respectively. The company has multiple pipeline milestones and expects annual NDA filings through 2031. Axsome reported $320M in cash and expects profitability soon.

Axsome Therapeutics expects AUVELITY prescriptions to grow over 1-2 quarters, with encouraging physician feedback. The company aims for $8B peak sales, including $4B each in major depressive disorder and Alzheimer's disease agitation. Axsome has expanded its commercial team and expects Q3 results to show launch progress. Management highlighted pipeline developments and cost expectations.

Piper Sandler maintained an Overweight rating on Axsome Therapeutics with a $258 price target, implying a 20.4% upside from the Sep 17 close of $214.28. The firm cited strong new prescription growth and a positive future outlook for the company, driven by increased demand in the MDD segment and early contributions from Alzheimer's disease agitation treatments.

Axsome Therapeutics (AXSM) and Revolution Medicines (RVMD) present distinct investment opportunities. Axsome, with three marketed CNS drugs, reported $638.5M revenue in 2025 but a net loss of $183.2M. Revolution, a clinical-stage oncology firm, had no revenue and a $1.1B net loss. Axsome trades at a premium, while Revolution's valuation is harder to assess. The author prefers Revolution due to its potential FDA approval for a pancreatic cancer drug in 2026.